Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Dec. 18 (Bloomberg) -- GlaxoSmithKline’s Revolade wins backing of health-cost agency in draft guidance on treatment of a rare bleeding disorder after drugmaker agrees to sell it to state-run medical system at a discount.

* Revolade is cost-effective for chronic immune

thrombocytopenic purpura in certain adults who have had

their spleens removed and those who haven’t responded to at

least one other therapy, National Institute for Health and

Clinical Excellence says in e-mailed statement * Decision reverses 2010 ruling that drug was too costly;

agency didn’t disclose size of discount Glaxo is offering


For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.